Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774520 | PMC |
| http://dx.doi.org/10.1016/j.hrcr.2023.09.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrafraction Patient Positional Uncertainty in Lung Stereotactic Ablative Radiotherapy with Abdominal Compression.
Pract Radiat Oncol
December 2024
Department of Radiation Oncology, Willis Knighton Cancer Center, 2600 Kings Highway, Shreveport, Louisiana, USA 71103 &, Department of Clinical Research, University of Jamestown, Fargo, ND, USA. Electronic address:
Purpose: Motion management presents a significant challenge in thoracic stereotactic ablative radiotherapy (SABR). Currently, a 5.0 mm standard planning target volume (PTV) margin is widely used to ensure adequate dose to the tumor.
View Article and Find Full Text PDFFeasibility and potential clinical benefit of dose de-escalation in stereotactic ablative radiotherapy for lung cancer lesions with ground glass opacities.
Phys Imaging Radiat Oncol
October 2024
Department of Radiation Oncology, Hospital Clínic, Barcelona Spain.
Introduction: Treatment of neoplasic lung nodules with ground glass opacities (GGO) faces two primary challenges. First, the standard practice of treating GGOs as solid nodules, which effectively controls the tumor locally, but might increase associated toxicities. The second is the potential for dose calculation errors related to increased heterogeneity.
View Article and Find Full Text PDFStereotactic Cardiac Radiotherapy for Refractory Ventricular Tachycardia in Structural Heart Disease Patients: A Systematic Review.
Europace
December 2024
Department of Cardiovascular Medicine, The University of Kansas Medical Center, Kansas City, Kansas.
Background: Among patients with structural heart disease with ventricular tachycardia (VT) refractory to medical therapy and catheter ablation, cardiac stereotactic body radiotherapy (SBRT) is a paradigm-changing treatment option.
Aims: To assess the efficacy of cardiac SBRT in refractory VT by comparing the rates of VT episodes, anti-tachycardia pacing (ATP) therapies, and implantable cardioverter-defibrillator (ICD) shocks post-SBRT with pre-SBRT.
Methods: We performed a comprehensive literature search and included all clinical studies reporting outcomes on cardiac SBRT for VT.
Understanding the PULSAR effect in combined radiotherapy and immunotherapy using transformer-based attention mechanisms.
Front Oncol
December 2024
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
PULSAR (personalized, ultra-fractionated stereotactic adaptive radiotherapy) is the adaptation of stereotactic ablative radiotherapy towards personalized cancer management. It has potential to harness the synergy between radiation therapy and immunotherapy, such as immune checkpoint inhibitors to amplify the anti-tumor immune response. For the first time, we applied a transformer-based attention mechanism to investigate the underlying interactions between combined PULSAR and PD-L1 blockade immunotherapy, based on the preliminary experimental results of a murine cancer model (Lewis Lung Carcinoma, LLC).
View Article and Find Full Text PDFStereotactic ablative radiotherapy for primary kidney cancer - An international patterns of practice survey.
Clin Transl Radiat Oncol
January 2025
Department of Oncology, Division of Radiation Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
Purpose: To conduct an international survey of radiation oncologists treating primary renal cell carcinoma (RCC) with SABR to ascertain the general patterns of SABR use, common dose/treatment/follow-up details, and expected outcomes.
Materials And Methods: A 51-question survey was created containing the following themes: prevalence and clinical scenarios in which RCC SABR is used, dose-fractionation schedules, treatment delivery details, follow-up/outcome assessments, and implementation barriers. The survey was distributed widely across multiple influential radiation oncology societies and social media, and ran from January to April 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!